Adlai Nortye Goodwill and Intangible Assets 2024-2024 | ANL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adlai Nortye goodwill and intangible assets from 2024 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Adlai Nortye Goodwill and Intangible Assets 2024-2024 | ANL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adlai Nortye goodwill and intangible assets from 2024 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$209.6B
Amgen (AMGN)	$149.1B
Gilead Sciences (GILD)	$130.2B
Vertex Pharmaceuticals (VRTX)	$125.6B
Bristol Myers Squibb (BMY)	$100.2B
CSL (CSLLY)	$74.3B
GSK (GSK)	$74.1B
Regeneron Pharmaceuticals (REGN)	$61.6B
Argenex SE (ARGX)	$36.2B
Alnylam Pharmaceuticals (ALNY)	$30.5B
BioNTech SE (BNTX)	$23.7B
BeiGene (ONC)	$22.8B
Biogen (BIIB)	$17.4B
Genmab (GMAB)	$13.3B
Genmab (GNMSF)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.3B
Illumina (ILMN)	$11.3B
Incyte (INCY)	$11.3B
Ascendis Pharma (ASND)	$10.1B
Exelixis (EXEL)	$10B
Swedish Orphan Biovitrum (BIOVF)	$9.6B
Moderna (MRNA)	$9.6B
QIAGEN (QGEN)	$9B
Exact Sciences (EXAS)	$7.7B
Bio-Techne Corp (TECH)	$7.6B
Repligen (RGEN)	$7.3B
Halozyme Therapeutics (HALO)	$7.3B
Roivant Sciences (ROIV)	$7.2B
Revolution Medicines (RVMD)	$6.8B